

AMARIN CORP PLC\UK
Form 424B3
May 27, 2010

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-163704

PROSPECTUS SUPPLEMENT NO. 1

(To prospectus dated January 26, 2010)

119,512,556 Ordinary Shares

AMARIN CORPORATION PLC

This prospectus supplement no. 1 (this Supplement) supplements and amends the prospectus dated January 26, 2010 (the Prospectus), which relates to the sale of up to 119,512,556 of our ordinary shares, par value £0.50 per share (Ordinary Shares), each represented by one American Depositary Share (ADS), of Amarin Corporation plc, by the selling shareholders named in the Prospectus or their transferees, pledgees, donees or other successors in interest. This Supplement does not relate to our issuance of additional Ordinary Shares or ADSs beyond the 119,512,556 originally covered by the Prospectus.

This Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus, which is to be delivered with this Supplement. This Supplement is qualified by reference to the Prospectus, except to the extent that the information in this Supplement updates and supersedes the information contained in the Prospectus.

Our ADSs are listed on the NASDAQ Capital Market, the principal trading market for our securities, under the symbol AMRN.

INVESTING IN THE SECURITIES INVOLVES RISKS. SEE RISK FACTORS BEGINNING ON PAGE 5 OF THE PROSPECTUS FILED ON JANUARY 26, 2010 TO READ ABOUT FACTORS YOU SHOULD CONSIDER BEFORE BUYING THE SECURITIES. BEFORE BUYING THESE SECURITIES, YOU SHOULD READ AND CONSIDER THE INFORMATION THAT AMARIN CORPORATION PLC FILES WITH THE SECURITIES AND EXCHANGE COMMISSION.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this Supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement no. 1 is May 27, 2010.

Edgar Filing: AMARIN CORP PLC\UK - Form 424B3

The information in the table appearing under the caption "Selling Shareholders" commencing on page 38 of the Prospectus is hereby supplemented and amended by adding the information below with respect to selling shareholders not previously listed in the Prospectus, and by superseding the information with respect to selling shareholders listed below as of or prior to the date of this Supplement.

The information set forth in the table below is current as of May 6, 2010. Since the date on which we were provided with the information regarding their security ownership in Amarin Corporation plc, selling shareholders may have acquired, sold, transferred or otherwise disposed of all or a portion of their securities. Accordingly, the information provided herein and in the Prospectus for any particular shareholder may understate or overstate, as the case may be, such shareholder's current ownership.

Selling Shareholder	Ordinary		Ordinary	Percentage of	
	Shares Owned	Percentage		Ordinary	Ordinary
	Prior to	Percentage	Ordinary	Ordinary	
	Offering	of Ordinary	Shares to be	Shares to be	
	(Including Ordinary	Shares Owned	Ordinary	owned upon	owned upon
	Shares underlying	Prior to	Shares to be	completion of	completion of
	warrants)	Offering (1)	Offered	offering	offering
Ramius Navigation Master Fund Ltd.(4)(14)					
c/o Ramius LLC					
599 Lexington Ave					
20 th Floor					
New York, NY 10022	56,250	0.06%	56,250	0	0%
Ramius Enterprise Master Fund Ltd. (14)					
c/o Ramius LLC					
599 Lexington Ave					
20 th Floor					
New York, NY 10022	0	0.00%	0	0	0%
Biomedical Institutional Value Fund, L.P.(4)(15)					
c/o Great Point Partners, LLC					
165 Mason Street					
3 rd Floor					
Greenwich, CT 06830	1,450,807	1.46%	1,450,807	0	0%
Biomedical Value Fund, L.P.(4)(15)	5,521,471	5.49%	5,521,471	0	0%
c/o Great Point Partners, LLC					

Edgar Filing: AMARIN CORP PLC\UK - Form 424B3

165 Mason Street

3rd Floor

Greenwich, CT 06830

- (1) Based on the number of Ordinary Shares outstanding on May 6, 2010, and calculated in accordance with Rule 13d-3 of the Exchange Act.
- (4) Pursuant to the terms of the 2009 Private Placement, the selling stockholder has certain registration rights and rights of first refusal to purchase up to its pro rata share of any offering by the Company of Ordinary Shares or any other class or series of its capital stock.
- (14) Ramius Enterprise Master Fund Ltd. transferred to Ramius Navigation Master Fund Ltd. warrants to purchase 56,250 shares of our common stock.
- (15) Biomedical Value Fund, L.P. transferred to Biomedical Institutional Value Fund, L.P. 963,270 shares of our common stock and warrants to purchase 487,537 shares of our common stock.